Dasatinib and quercetin with CAR-T therapy for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether adding two drugs, dasatinib and quercetin, to CAR-T therapy can help people with multiple myeloma that has come back or not responded to past treatments. It aims to make the CAR-T cells work better and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have multiple myeloma that has returned or not responded to at least 3 prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
- You have been prescribed Carvykti (a CAR-T therapy) as your treatment.
- You are generally able to care for yourself (ECOG performance status 0, 1, or 2).
- Your blood and organ function are within acceptable limits (e.g., hemoglobin, white blood cell count, platelet count, liver and kidney function tests).
- You are not pregnant, nursing, or planning to have children during the study, and you agree to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines two types of therapy: CAR T-cell therapy (which uses your own immune cells to fight the cancer) and daratumumab (a drug that targets a protein on myeloma cells). The goal is to see if this combination can help people with relapsed or refractory multiple myeloma.
This trial tests giving an immunotherapy drug (talquetamab) before CAR T-cell therapy (cilta-cel) to see if it helps people with multiple myeloma that has come back or stopped responding to other treatments.
This trial tests an investigational CAR-T cell therapy (anitocabtagene autoleucel) in people with newly diagnosed multiple myeloma. It aims to see if this treatment is safe and effective when given after a short course of standard chemotherapy.
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This trial tests a new kind of CAR-T cell therapy (called APRIL-BAFF-Bicephali CAR-T) for people with multiple myeloma that has come back or not responded to treatment. It aims to see if this therapy is safe and can help when other treatments have stopped working.
Hear when a new Recurrent Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.